Investigational drug · Phase 3
CM512
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
8 still active
All registered trials
10
Any phase or sponsor naming "CM512"
First trial start
2025
Jun 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CM512", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Rhinosinusitis With Nasal Polyposis
- Chronic Spontaneous Urticaria (CSU)
- Asthma
- Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
- Atopic Dermatitis
- Perennial Allergic Rhinitis (PAR)
- Atopic Dermatitis (AD)
- Chronic Obstructive Pulmonary Disease
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Chronic hives (urticaria) · Asthma · COPD · Allergies (allergic rhinitis) · Immunology and inflammation · Respiratory · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "CM512" as an intervention, largest first.
- A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.Pivotal-lookingRecruiting
Keymed Biosciences Co.LtdIndustry
NCT07230483 · 246 participants (planned) · Start Dec 2025 · Primary completion Dec 2027
Drug: CM512 · For: Atopic Dermatitis (AD)
Sites: Beijing, China
- A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-3)Pivotal-lookingNot yet recruiting
Beijing Keymed Biosciences Co., Ltd.Industry
NCT07807826 · 240 participants (planned) · Start Oct 2026 · Primary completion Nov 2027
Drug: CM512; Placebo · For: Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Sites: Beijing, China
- A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingNot yet recruiting
Keymed Biosciences Co.LtdIndustry
NCT06980142 · 204 participants (planned) · Start Jun 20, 2025 · Primary completion Mar 17, 2028
Drug: CM512; Placebo · For: Chronic Obstructive Pulmonary Disease
- Study of CM512 Injection in Subjects With Moderate-to-severe AsthmaPivotal-lookingRecruiting
Keymed Biosciences Co.LtdIndustry
NCT07011524 · 200 participants (planned) · Start Aug 19, 2025 · Primary completion Jul 21, 2027
Drug: CM512 injection; Placebo · For: Asthma
Sites: Guangzhou, China
- Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background TherapyPivotal-lookingNot yet recruiting
Beijing Keymed Biosciences Co., Ltd.Industry
NCT07890350 · 200 participants (planned) · Start Oct 2026 · Primary completion Jun 2028
Drug: CM512; Placebo · For: Perennial Allergic Rhinitis (PAR)
Sites: Beijing, China
- Study of CM512 in Patients With Moderate-to-Severe Atopic DermatitisPivotal-lookingRecruiting
Keymed Biosciences Co.LtdIndustry
NCT06947980 · 200 participants (planned) · Start Jun 19, 2025 · Primary completion Jul 18, 2026
Drug: Placebo Comparator; CM512 · For: Atopic Dermatitis
Sites: Beijing, China
- A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-1)Pivotal-lookingCompleted
Beijing Keymed Biosciences Co., Ltd.Industry
NCT06930612 · 120 participants · Start Jun 12, 2025 · Primary completion Apr 20, 2026
Drug: CM512; Placebo · For: Chronic Rhinosinusitis With Nasal Polyposis
Sites: Beijing, China
- A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-2)Not yet recruiting
Keymed Biosciences Co.LtdIndustry
NCT07519577 · 120 participants (planned) · Start May 31, 2026 · Primary completion May 31, 2028
Drug: CM512 · For: Chronic Rhinosinusitis With Nasal Polyposis
Sites: Beijing, China
- Study of CM512 in Healthy Subjects and Patients With Atopic DermatitisPivotal-lookingCompleted
Keymed Biosciences Co.LtdIndustry
NCT06553209 · 110 participants · Start Sep 2, 2024 · Primary completion Aug 26, 2025
Drug: CM512; Placebo · For: Atopic Dermatitis
Sites: Chengdu, China
Keymed Biosciences Co.LtdIndustry
NCT07166211 · 48 participants (planned) · Start Nov 27, 2025 · Primary completion Nov 2, 2026
Drug: CM512 injection; placebo · For: Chronic Spontaneous Urticaria (CSU)
Sites: Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
- The dawn of the dual-target era in respiratory disease: promise, pitfalls, and a roadmap for bispecific antibodies.
Cheng Y, Ding J, Li Z, et al. · Front Immunol 2026
- First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity.
Cheng Y, Liu Q, Li M, et al. · Front Immunol 2026
- CM512, a potentially novel IgG1-based bispecific antibody dual-targeting TSLP and IL-13, for the suppression of type 2 inflammation.
Yang Y, Lan Y, Bian L, et al. · J Transl Med 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.